Phase III Factive data

Oscient (OSCI) said its Factive gemifloxacin met the primary endpoints in two Phase III trials in acute bacterial rhinosinusitis. In the first double-blind trial in 356 evaluable patients, 87.3% and 86.9% of those given Factive for five and seven days, respectively, showed clinical success, sufficient improvement or resolution of symptoms, the primary endpoint. In the second trial in 216 patients, 90.3% of patients given Factive for five days had eradication or presumed eradication of initial pathogens without new infection at follow-up, the primary endpoint. ...